International Psoriasis Council

Apply for fellowship
Support our work
subscribe
Covid-19 resource Center
Advancing Knowledge. Enhancing Care.
subscribe
Covid-19 resource Center

Advancing Knowledge. Enhancing Care.

WELCOME TO THE
INTERNATIONAL PSORIASIS COUNCIL

Meet Our Experts

Search IPC’s network of psoriasis experts across the globe.

Search Directory

View Upcoming Events

Take a look at upcoming IPC symposia and events.
View Events

Browse Resource Library

Learn about the latest in psoriasis research and treatment guidelines.

Search Resources
Subscribe here for home page

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

The Latest Psoriasis News

Lilly Press Release Graphic

Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)

Eli Lilly announced a new formula for Taltz® that contains the same active ingredient as the original formulation, but patients experience significantly less pain at the injection site.
Read More

Arcutis Announces FDA Approval for ZORYVE (Roflumilast) Cream 0.3% for Plaque Psoriasis in Individuals Age 12 and Older

ZORYVE is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to be available mid-August.
Read More
Arcutis Press Release Graphic
2022_radlacongress_report

Un Enfoque en Psoriasis: Un Reporte de el Congreso RADLA 2022

La XXXIX Reunión Anual de Dermatólogos Latinoamericanos (RADLA) se realizó de manera virtual del 2 al 5 de mayo, siendo CHILE el país anfitrión. El programa incluyó más de 400 sesiones científicas, 400 expositores renombrados en dermatología y venereología, y más de 3000 asistentes de 17 países participantes. Este reporte incluye el resumen de 11 presentaciones que tuvieron como centro la psoriasis.
Read More

Latest Resources

Support Our Work

We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.

Learn How